News Release

INDIANAPOLIS, Oct. 8, 2024— Today, Eli Lilly and Company (NYSE: LLY) announced the appointment of Thomas J. Fuchs, Dr.sc., as its first chief AI officer, effective Oct. 21, 2024. In this role, Fuchs will provide vision, strategic direction and overall leadership of AI initiatives across Lilly, including drug discovery, clinical trials, manufacturing, commercial activities and internal functions. He will also identify, build and manage AI and machine learning solutions to help Lilly provide medicines to patients around the world.

Before joining Lilly, Fuchs was the dean and inaugural department chair for AI and Human Health at Mount Sinai, director of the Hasso Plattner Institute for Digital Health at Mount Sinai, and the endowed Barbara T. Murphy professor for AI and computational pathology at the Icahn School of Medicine at Mount Sinai. Prior, Fuchs held positions at Memorial Sloan Kettering Cancer Center, NASA's Jet Propulsion Laboratory and the California Institute of Technology, and founded three companies, including Paige AI. Fuchs holds a doctoral degree in machine learning from ETH Zurich and a master’s in technical mathematics from Graz Technical University in Austria.

“In this new era of technology, the potential for artificial intelligence and machine learning to revolutionize health care is immense,” said Diogo Rau, Lilly executive vice president and chief information and digital officer. “Dr. Fuchs will contribute to Lilly’s breakthroughs in AI, aiding in the discovery and development of new medicines while enhancing patient outcomes. We are committed to leveraging these cutting-edge technologies to drive innovation and make a meaningful impact on lives around the world.”

“Lilly is at the forefront of health care innovation, and I’m tremendously excited to join this talented team at such a pivotal time in technological advancement,” said Fuchs. “Throughout my career, I have focused on leveraging technology to help patients and enhance human health. Joining Lilly will allow me to expand this mission worldwide on an amazing scale. Building AI to benefit millions of patients is profoundly humbling.”

About Lilly

Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram and LinkedIn. C-LLY

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995), including about Lilly’s leadership and the company’s strategic plans and potential artificial intelligence initiatives, reflecting Lilly’s current beliefs and expectations. However, there can be no assurances of achieved objectives or strategy execution as planned. For further discussion of risks and uncertainties relevant to Lilly’s business that could cause actual results to differ from Lilly’s expectations, see Lilly’s Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.